Enas Al Zaghal, MD
Endocrinology, Diabetes & Metabolism · Norfolk, NENPI 1689014730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,003 and has fallen 52.7% since, to $474 in 2025.
Across 299 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$905
- Novo Nordisk$474
- Sanofi-aventis U.S. LLC$341
- Amgen$282
- Bayer$246
- Corcept Therapeutics$239
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$601%
- Food & beverage$5,01598%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 68 | $905 |
| Novo Nordisk | 25 | $474 |
| Sanofi-aventis U.S. LLC | 16 | $341 |
| Amgen | 18 | $282 |
| Bayer | 14 | $246 |
| Corcept Therapeutics | 13 | $239 |
| AstraZeneca(2 entities) | 16 | $216 |
| Xeris Pharmaceuticals, Inc. | 11 | $214 |
| Incyte Corporation | 2 | $199 |
| Tandem Diabetes Care, Inc. | 12 | $188 |
| Ascensia Diabetes Care US Inc. | 10 | $150 |
| Insulet Corporation | 8 | $149 |
| Recordati_rare_diseases_inc. | 7 | $148 |
| Boehringer Ingelheim | 8 | $121 |
| Amarin Pharma, Inc. | 7 | $120 |
| Zealand Pharma US, Inc. | 7 | $101 |
| Medtronic(2 entities) | 6 | $98 |
| Abbott | 5 | $87 |
| Mannkind Corporation | 5 | $85 |
| Merck | 6 | $82 |
| Kyowa Kirin, Inc. | 5 | $80 |
| Astellas Pharma US Inc | 4 | $71 |
| Ascendis Pharma Endocrinology Inc | 4 | $70 |
| Rhythm Pharmaceuticals, Inc. | 1 | $58 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| Dexcom, Inc. | 3 | $48 |
| Shire North American Group Inc | 3 | $44 |
| Chiesi USA, Inc. | 2 | $42 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| Myriad Genetic Laboratories, Inc. | 1 | $29 |
| IBSA Pharma Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $22 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Valeritas, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| BETA Bionics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,095 in reported general payments places this provider in the 70th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $636,026 |
| MounjaroTirzepatide | 389 | $437,663 |
| OzempicSemaglutide | 296 | $341,102 |
| Tresiba Flextouch U-200Insulin Degludec | 145 | $172,176 |
| JardianceEmpagliflozin | 181 | $157,015 |
| FarxigaDapagliflozin Propanediol | 164 | $126,234 |
| TrulicityDulaglutide | 107 | $123,185 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 77 | $93,353 |
| KerendiaFinerenone | 107 | $85,535 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $76,061 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 80 | $57,513 |
| VascepaIcosapent Ethyl | 114 | $46,246 |
| Tresiba Flextouch U-100Insulin Degludec | 43 | $25,309 |
| Humalog Kwikpen U-100Insulin Lispro | 86 | $23,560 |
| Repatha SureclickEvolocumab | 34 | $23,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $239 | $636,02611 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Baqsimi | $905 | $578,164528 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $474 | $369,498381 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $121 | $177,633207 claims |
| AstraZenecaFarxiga | $216 | $126,234164 claims |
| BayerKerendia | $246 | $85,535107 claims |
| MerckJanuvia | $82 | $12,57917 claims |
| IBSA Pharma Inc.Tirosint-Sol | $25 | $4,35514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Norfolk
- Kaitlin BrauNorfolk$8K
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Shannon WakeleyLincoln$78K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.